EXPAND TAVR II Pivotal Trial evaluating the Evolut™ TAVR platform in a new patient population Medtronic today announced the first patient enrollment in the EXPAND TAVR II Pivotal Trial, the first randomized clinical trial evaluating the self-expanding, supra-annular Evolut™ TAVR […]

EuroPCR: Low Risk Study Demonstrates Hemodynamic Advantages of Evolut™ Transcatheter Aortic Valve Replacement (TAVR) System Over Open Heart Surgery Out to Two Years DUBLIN, May 18, 2021 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the […]